Zika Virus Replicons for Drug Discovery

Xuping Xie, Jing Zou, Chao Shan, Yujiao Yang, Dieudonné Buh Kum, Kai Dallmeier, Johan Neyts, Pei-Yong Shi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The current epidemic of Zika virus (ZIKV) has underscored the urgency to establish experimental systems for studying viral replication and pathogenesis, and countermeasure development. Here we report two ZIKV replicon systems: a luciferase replicon that can differentiate between viral translation and RNA synthesis; and a stable luciferase replicon carrying cell line that can be used to screen and characterize inhibitors of viral replication. The transient replicon was used to evaluate the effect of an NS5 polymerase mutation on viral RNA synthesis and to analyze a known ZIKV inhibitor. The replicon cell line was developed into a 96-well format for antiviral testing. Compare with virus infection-based assay, the replicon cell line allows antiviral screening without using infectious virus. Collectively, the replicon systems have provided critical tools for both basic and translational research.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalEBioMedicine
Volume12
DOIs
StatePublished - Oct 1 2016

Fingerprint

Replicon
Drug Discovery
Viruses
Cells
Viral RNA
Luciferases
Cell Line
Antiviral Agents
Translational Medical Research
Virus Diseases
Zika Virus
Assays
Screening
RNA
Mutation
Testing

Keywords

  • Drug discovery
  • Flavivirus
  • Replicon
  • Zika

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Xie, X., Zou, J., Shan, C., Yang, Y., Kum, D. B., Dallmeier, K., ... Shi, P-Y. (2016). Zika Virus Replicons for Drug Discovery. EBioMedicine, 12, 156-160. https://doi.org/10.1016/j.ebiom.2016.09.013

Zika Virus Replicons for Drug Discovery. / Xie, Xuping; Zou, Jing; Shan, Chao; Yang, Yujiao; Kum, Dieudonné Buh; Dallmeier, Kai; Neyts, Johan; Shi, Pei-Yong.

In: EBioMedicine, Vol. 12, 01.10.2016, p. 156-160.

Research output: Contribution to journalArticle

Xie, X, Zou, J, Shan, C, Yang, Y, Kum, DB, Dallmeier, K, Neyts, J & Shi, P-Y 2016, 'Zika Virus Replicons for Drug Discovery', EBioMedicine, vol. 12, pp. 156-160. https://doi.org/10.1016/j.ebiom.2016.09.013
Xie X, Zou J, Shan C, Yang Y, Kum DB, Dallmeier K et al. Zika Virus Replicons for Drug Discovery. EBioMedicine. 2016 Oct 1;12:156-160. https://doi.org/10.1016/j.ebiom.2016.09.013
Xie, Xuping ; Zou, Jing ; Shan, Chao ; Yang, Yujiao ; Kum, Dieudonné Buh ; Dallmeier, Kai ; Neyts, Johan ; Shi, Pei-Yong. / Zika Virus Replicons for Drug Discovery. In: EBioMedicine. 2016 ; Vol. 12. pp. 156-160.
@article{baf9362c758a49d88d0449917704737f,
title = "Zika Virus Replicons for Drug Discovery",
abstract = "The current epidemic of Zika virus (ZIKV) has underscored the urgency to establish experimental systems for studying viral replication and pathogenesis, and countermeasure development. Here we report two ZIKV replicon systems: a luciferase replicon that can differentiate between viral translation and RNA synthesis; and a stable luciferase replicon carrying cell line that can be used to screen and characterize inhibitors of viral replication. The transient replicon was used to evaluate the effect of an NS5 polymerase mutation on viral RNA synthesis and to analyze a known ZIKV inhibitor. The replicon cell line was developed into a 96-well format for antiviral testing. Compare with virus infection-based assay, the replicon cell line allows antiviral screening without using infectious virus. Collectively, the replicon systems have provided critical tools for both basic and translational research.",
keywords = "Drug discovery, Flavivirus, Replicon, Zika",
author = "Xuping Xie and Jing Zou and Chao Shan and Yujiao Yang and Kum, {Dieudonn{\'e} Buh} and Kai Dallmeier and Johan Neyts and Pei-Yong Shi",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.ebiom.2016.09.013",
language = "English (US)",
volume = "12",
pages = "156--160",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Zika Virus Replicons for Drug Discovery

AU - Xie, Xuping

AU - Zou, Jing

AU - Shan, Chao

AU - Yang, Yujiao

AU - Kum, Dieudonné Buh

AU - Dallmeier, Kai

AU - Neyts, Johan

AU - Shi, Pei-Yong

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The current epidemic of Zika virus (ZIKV) has underscored the urgency to establish experimental systems for studying viral replication and pathogenesis, and countermeasure development. Here we report two ZIKV replicon systems: a luciferase replicon that can differentiate between viral translation and RNA synthesis; and a stable luciferase replicon carrying cell line that can be used to screen and characterize inhibitors of viral replication. The transient replicon was used to evaluate the effect of an NS5 polymerase mutation on viral RNA synthesis and to analyze a known ZIKV inhibitor. The replicon cell line was developed into a 96-well format for antiviral testing. Compare with virus infection-based assay, the replicon cell line allows antiviral screening without using infectious virus. Collectively, the replicon systems have provided critical tools for both basic and translational research.

AB - The current epidemic of Zika virus (ZIKV) has underscored the urgency to establish experimental systems for studying viral replication and pathogenesis, and countermeasure development. Here we report two ZIKV replicon systems: a luciferase replicon that can differentiate between viral translation and RNA synthesis; and a stable luciferase replicon carrying cell line that can be used to screen and characterize inhibitors of viral replication. The transient replicon was used to evaluate the effect of an NS5 polymerase mutation on viral RNA synthesis and to analyze a known ZIKV inhibitor. The replicon cell line was developed into a 96-well format for antiviral testing. Compare with virus infection-based assay, the replicon cell line allows antiviral screening without using infectious virus. Collectively, the replicon systems have provided critical tools for both basic and translational research.

KW - Drug discovery

KW - Flavivirus

KW - Replicon

KW - Zika

UR - http://www.scopus.com/inward/record.url?scp=84992646605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992646605&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2016.09.013

DO - 10.1016/j.ebiom.2016.09.013

M3 - Article

VL - 12

SP - 156

EP - 160

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -